Gilead Sciences, Inc. receives a $271,000 investment from Burt Wealth Advisors

In the quarter ending in December, Burt Wealth Advisors made a new position in Gilead Sciences, INC (NASDAQ: GILD), according to the most recent statement the company filed with the Securities and Exchange Commission.

‍

For around $270,000, the fund purchased 3,154 shares in the pharmaceutical company.

‍

Some significant investors have increased or decreased the quantity of stock they currently own. During the last quarter of the fiscal year, Jacobs & Co CA increased its holding in Gilead Sciences by 0.5%. Jacobs & Co CA purchased a another 127 shares during the questioned period, for a total of 26,986 shares of the biopharmaceutical company's stock, valued at $2,316,000.

‍

During the third quarter, Capital Advisors Ltd LLC increased its ownership stake in Gilead Sciences to 29.4%. With the purchase of an additional 138 shares during the relevant period, Capital Advisors Ltd LLC now owns 607 shares of the biopharmaceutical company's stock, valued at $37,000.

‍

Mastrapasqua Asset Management INC increased its ownership stake in Gilead Sciences by 4.5% during the third quarter.

‍

Mastrapasqua Asset Management INC now owns 3,494 shares of the biopharmaceutical company, which they acquired for $216,000 after adding an additional 150 shares during the period. Gilead Sciences saw a 1.7% increase in GHP Investment Advisors INC's assets during the third period of current fiscal year.

‍

GHP Investment Advisors INC now owns 8,951 shares of stock in the biopharmaceutical industry, valued at $522,000, following further acquisitions made during the relevant period.

‍

Not to mention, JFS Financial Advisors LLC increased its shareholdings in Gilead Sciences by 68.1% during the third quarter. JFS Financial Advisors LLC now owns 400 shares of the biopharmaceutical company, valued at $, after acquiring 162 more shares during the last period.

‍

78.72% of the company's stock is held by hedge funds and institutional investors.

Business insider Merdad Parsey sold 6,126 shares of the company's stock on Monday, March 13, according to other news sources.

‍

The stock was sold for $483,892.74 at an average cost of $78.99 per share, generating a total profit. Upon the transaction's conclusion, the insider will now have 70,130 company shares, for a total of $5,539,568.70.

‍

The Securities and Exchange Commission was informed about the transaction through a filing, which was then made public on the SEC's website.

‍

Gilead Sciences, Inc. receives a $271,000 investment from Burt Wealth Advisors

Shares of Gilead Sciences decreased by $0.09 to $79.05. Wednesday at the height of the working day.

‍

The company traded 829,480 shares, increasing its overall share count to 6,337,501.

‍

Now, the quick ratio is 1.15, the current ratio is 1.29, and the debt-to-equity ratio is 1.14.

‍

The share price has a rolling average of $82.93 for the past 50 days and a moving average of $78.83 for the past 200 days. Gilead Sciences, INC experienced a low point last year of $57.17 and a high point last year of $89.74.

‍

The price-to-earnings ratio, price-to-earnings-growth ratio, and beta value of the company are all 0.92, 0.38, and 0.38 respectively.

‍

The market capitalization of the company is $98.58 billion.

‍

Gilead Sciences (NASDAQ: GILD) made its earnings public on Thursday, February 2.

‍

The biopharmaceutical industry posted earnings of $1.67 per share in the fourth quarter, which was $0.17 more than the $1.50 per share average estimate.

‍

Gilead Sciences' net margin was 16.83%, and the company's return on equity was 44.46%.

‍

The company's actual revenues for the quarter were $7.39 billion, which was much more than the $6.63 billion average projection.

‍

In the previous year, the company made earnings of $0.69 per share. Revenue increased by 2.0% year over year when compared to the same quarter's statistics from the prior year. Gilead Sciences, INC is expected to earn $6.86 per share during the current fiscal year, according to sell-side analysts.

‍

Also, the business disclosed a dividend payment that would be paid on March 30.

‍

Stockholders of record on March 15 will receive a dividend payment of $0.75.

‍

This dividend's ex-dividend date is March 14.

‍

This leads in a dividend yield of 3.80% and a dividend payout of $3 per year.

‍

Gilead Sciences' quarterly dividend, which was formerly $0.73, has increased. Gilead Sciences distributes 82.19% of its revenue to its stockholders.

‍

Researchers and analysts have concentrated their attention on GILD in a number of studies.

‍

The pricing range Robert W.

‍

As a result of a research note that was released on February 3rd, Baird has lifted its price target for Gilead Sciences from $69 to $80.00. In a research note released on December 13, Bank of America reiterated its "neutral" rating on Gilead Sciences' shares and set the company's price objective at $85.00 per share. In a research note released on Friday, February 3, Leerink rated SVB Gilead Sciences as "market perform."

‍

Moreover, Leerink raised the target price for Gilead Sciences from $80.00 to $90.00. In a research note released on January 3 by Wells Fargo & Company, Gilead Sciences was given a "equal weight" rating.

‍

Moreover, the firm's target price for Gilead Sciences rose from $75.00 to $90.00. On Friday, February 10, Cowen raised their price target on Gilead Sciences from $90.00 to $95.00 in a research note. Eight research analysts have recommended buying the stock, nine have given it a hold rating, and one has given it a strong buy rating.

‍

The company currently has a consensus rating of "Moderate Buy" on Trade Algo, and the consensus price for its price objective is $89.40.

‍